POINT Biopharma Global affirmed that the SPLASH clinical trial for the PSMA-targeted PNT2002 program is not experiencing any manufacturing or drug supply issues or delays. In-house production of no-carrier-added 177Lu at POINT’s Indianapolis facility is expected to commence by the end of 2023. In addition to its manufacturing facility in Indianapolis, Indiana, POINT also maintains active relationships with radiopharmaceutical contract manufacturers and isotope suppliers across multiple geographies. Establishing redundancy across every key business area is a pillar of POINT’s value proposition to physicians and patients, and to ensure resiliency to radiopharmaceutical supply chain disruptions.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PNT:
- POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
- POINT Biopharma to Participate in Upcoming Investor Conferences
- Point Biopharma completes randomization in PNT2002’s Phase 3 Splash trial
- POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
